XML 35 R15.htm IDEA: XBRL DOCUMENT
v3.22.4

Restructuring and impairment charges | 12 Months Ended
--- | ---
Dec. 31, 2022
Restructuring and Related Activities [Abstract] |
Restructuring and impairment charges | Restructuring and impairment charges 2022 restructuring plan On November 15, 2022, we initiated a strategic restructuring plan designed to improve operating performance and position the organization to deliver long-term durable growth by creating efficiencies that align with our high growth strategic objectives (the “2022 restructuring plan”). The plan primarily involves the relocation of certain manufacturing operations to existing lower-cost locations in addition to the streamlining of various business functions across the organization and related workforce reductions. These actions are expected to be substantially completed during 2023. The following table provides a summary of the cost estimates by major type of expense associated with the 2022 restructuring plan:
| Total estimated amount expected to be incurred
Plan expense estimates: | (Dollars in millions)
Termination benefits | $18 million to $22 million
Other costs (1) | $1 million to $1 million
Restructuring Charges | $19 million to $23 million
Restructuring related charges (2) | $20 million to $25 million
Total restructuring and restructuring related charges | $39 million to $48 million
(1)Includes facility closure and outplacement costs. (2)Restructuring related charges represent costs that are directly related to the program and principally comprise costs to transfer manufacturing operations to the existing lower-cost locations, project management costs and accelerated depreciation. The plan also includes an $8.1 million non cash tax related charge arising from establishing a valuation allowance against a local deferred tax asset, which is no longer expected to be utilized as a result of the transfer. Excluding this tax charge, the majority of the restructuring related charges are expected to be recognized within cost of goods sold. We estimate that $26 million to $32 million of the restructuring and restructuring related charges will result in cash outlays, most of which are expected to be made in 2023. Additionally, we expect to incur approximately $2 million in aggregate capital expenditures under the plan, most of which is expected to be incurred during 2023. For the year ended December 31, 2022, we incurred $10.1 million in restructuring related charges, which were recognized in cost of goods sold and taxes on income from continuing operations. Respiratory divestiture plan During 2021 and in connection with the Respiratory business divestiture, we committed to a restructuring plan designed to separate the manufacturing operations to be transferred to Medline from those that will remain with Teleflex, which includes related workforce reductions (the “Respiratory divestiture plan”). The plan includes expanding certain of our existing locations to accommodate the transfer of capacity from the sites being transferred to Medline and replicating the manufacturing processes at alternate existing locations. We expect this plan will be substantially completed by the end of 2023. The following table provides a summary of our cost estimates by major type of expense associated with the Respiratory divestiture plan:
| Total estimated amount expected to be incurred
Plan expense estimates: | (Dollars in millions)
Restructuring charges (1) | $5 million to $8 million
Restructuring related charges (2) | $19 million to $22 million
Total restructuring and restructuring related charges | $24 million to $30 million
(1) Substantially all of the charges consist of employee termination benefit costs. (2)Consist of charges that are directly related to the Respiratory divestiture plan and principally constitute costs to transfer manufacturing operations to other locations and project management costs. Substantially all of the charges are expected to be recognized within costs of goods sold. We expect substantially all of the restructuring and restructuring related charges will result in future cash outlays. Additionally, we expect to incur $22 million to $28 million in aggregate capital expenditures under the plan. For the years ended December 31, 2022 and 2021, we incurred $8.9 million and $3.3 million, respectively, in pre-tax restructuring related charges, all of which were recognized in cost of goods sold. As of December 31, 2022, we have incurred net aggregate restructuring expenses related to the Respiratory divestiture plan of $3.3 million. Additionally, as of December 31, 2022, we have incurred net aggregate restructuring related charges in connection with the Respiratory divestiture plan of $12.2 million, which were primarily included in cost of goods sold. 2019 Footprint realignment plan In February 2019, we initiated a restructuring plan primarily involving the relocation of certain manufacturing operations to existing lower-cost locations and related workforce reductions (the “2019 Footprint realignment plan"). The plan is substantially complete and as a result, we expect future restructuring expenses associated with the plan, if any, to be immaterial. 2018 Footprint realignment plan In May 2018, we initiated a restructuring plan involving the relocation of certain European manufacturing operations to existing lower-cost locations, the outsourcing of certain European distribution operations and related workforce reductions (the "2018 Footprint realignment plan"). The plan is substantially complete and as a result, we expect future restructuring expenses associated with the plan, if any, to be immaterial. 2014 Footprint realignment plan In April 2014, we initiated a restructuring plan involving the consolidation of operations and a related reduction in workforce at certain facilities, and the relocation of manufacturing operations from certain higher-cost locations to existing lower-cost locations (the "2014 Footprint realignment plan"). The plan is substantially complete and as a result, we expect future restructuring expenses associated with the plan, if any, to be immaterial. The following table summarizes the restructuring reserve activity related to our 2022 restructuring plan, Respiratory divestiture plan as well as the 2019 and 2018 Footprint realignment plans:
| 2022 restructuring plan |  | Respiratory divestiture plan |  | 2019 Footprint realignment plan |  | 2018 Footprint realignment plan
Balance at December 31, 2020 (1) | $ | — |  |  | $ | — |  |  | $ | 8,054 |  |  | $ | 50,081 |
Subsequent accruals | — |  |  | 2,694 |  |  | 253 |  |  | 2,476 |
Cash payments | — |  |  | (7) |  |  | (4,982) |  |  | (4,813) |
Foreign currency translation and other | — |  |  | (86) |  |  | (19) |  |  | (3,679) |
Balance at December 31, 2021 (1) | — |  |  | 2,601 |  |  | 3,306 |  |  | 44,065 |
Subsequent accruals | 15,523 |  |  | 578 |  |  | (987) |  |  | 2,076 |
Cash payments | (978) |  |  | (149) |  |  | (874) |  |  | (24,310) |
Foreign currency translation and other | 315 |  |  | 19 |  |  | — |  |  | (3,292) |
Balance at December 31, 2022 (1) | $ | 14,860 |  |  | $ | 3,049 |  |  | $ | 1,445 |  |  | $ | 18,539 |
(1)The restructuring reserves as of December 31, 2022, 2021 and 2020 consisted mainly of accruals related to termination benefits. Other costs (facility closure, employee relocation, equipment relocation and outplacement costs) were expensed and paid in the same period. The restructuring and impairment charges recognized for the years ended December 31, 2022, 2021, and 2020 consisted of the following:
| 2022
| Termination benefits |  | Other Costs (1) |  | Total
2022 Restructuring plan | $ | 15,465 |  |  | $ | 58 |  |  | $ | 15,523 |
Respiratory divestiture plan | 504 |  |  | 74 |  |  | 578 |
2019 Footprint realignment plan | (1,120) |  |  | 133 |  |  | (987) |
2018 Footprint realignment plan | 1,230 |  |  | 846 |  |  | 2,076 |
Other restructuring programs (2) | 1,306 |  |  | 306 |  |  | 1,612 |
Total restructuring charges | 17,385 |  |  | 1,417 |  |  | 18,802 |
Asset impairment charges | — |  |  | 1,497 |  |  | 1,497 |
Total restructuring and impairment charges | $ | 17,385 |  |  | $ | 2,914 |  |  | $ | 20,299 |
| 2021
| Termination benefits |  | Other Costs (1) |  | Total
Respiratory divestiture plan | $ | 2,687 |  |  | $ | 7 |  |  | $ | 2,694 |
2021 Restructuring plan | 7,280 |  |  | 77 |  |  | 7,357 |
2019 Footprint realignment plan | (111) |  |  | 364 |  |  | 253 |
2018 Footprint realignment plan | 2,335 |  |  | 141 |  |  | 2,476 |
Other restructuring programs (3) | (429) |  |  | 2,648 |  |  | 2,219 |
Total restructuring charges | 11,762 |  |  | 3,237 |  |  | 14,999 |
Asset impairment charges | — |  |  | 6,739 |  |  | 6,739 |
Total restructuring and impairment charges | $ | 11,762 |  |  | $ | 9,976 |  |  | $ | 21,738 |
| 2020
| Termination benefits |  | Other Costs (1) |  | Total
2020 Workforce reduction plan | $ | 8,494 |  |  | $ | 353 |  |  | $ | 8,847 |
2019 Footprint realignment plan | 647 |  |  | 895 |  |  | 1,542 |
2018 Footprint realignment plan | 5,565 |  |  | 383 |  |  | 5,948 |
Other restructuring programs (4) | (72) |  |  | 838 |  |  | 766 |
Total restructuring charges | 14,634 |  |  | 2,469 |  |  | 17,103 |
Asset impairment charges | — |  |  | 21,388 |  |  | 21,388 |
Total restructuring and impairment charges | $ | 14,634 |  |  | $ | 23,857 |  |  | $ | 38,491 |
(1)Includes facility closure, contract termination and other exit costs. (2)Includes activity primarily related to a restructuring plan initiated in the first quarter of 2022 that is designed to relocate manufacturing operations at certain of our facilities, the 2014 Footprint realignment plan and the 2020 Workforce reduction plan, a program initiated in the second quarter of 2020. (3)Includes the 2020 Workforce reduction plan and the 2014 Footprint realignment plan. (4)Includes activity primarily related to the 2016 and 2014 Footprint realignment plans. Impairment Charges For the year ended December 31, 2022, we recorded impairment charges of $1.5 million related to our decision to abandon certain assets. For the year ended December 31, 2021, we recorded impairment charges of $6.7 million related to our decision to abandon intellectual property and other assets primarily associated with our respiratory product portfolio that was not transferred to Medline as part of the Respiratory business divestiture. For the year ended December 31, 2020, we recorded impairment charges of $21.4 million related to our decision to abandon intellectual property and other assets associated with our surgical product portfolio.

X
- References No definition available. + Details
Name: | us-gaap_RestructuringAndRelatedActivitiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets. + References No definition available. + Details
Name: | us-gaap_RestructuringImpairmentAndOtherActivitiesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration